Welcome to our dedicated page for Envista Holdings news (Ticker: NVST), a resource for investors and traders seeking the latest updates and insights on Envista Holdings stock.
Envista Holdings Corporation (NYSE: NVST) is a leading global dental products company committed to empowering dental professionals worldwide. Headquartered in Brea, California, Envista develops, manufactures, and markets an extensive portfolio of dental consumables, equipment, and services. The company operates through two primary segments: Specialty Products & Technologies and Equipment & Consumables.
The Specialty Products & Technologies segment focuses on dental implant systems, regenerative solutions, dental prosthetics, orthodontic systems, and lab products. This segment is dedicated to advancing the capabilities of dental professionals through innovative products and technologies.
The Equipment & Consumables segment offers a broad range of dental equipment and supplies used in dental offices, including digital imaging systems, software, and other visualization and magnification systems, supporting the diagnostic, treatment, and prevention needs of dental conditions.
Envista has a strong commitment to continuous improvement, action-oriented innovation, and a deep respect for dental professionals. Its comprehensive product portfolio covers an estimated 90% of dentists’ clinical needs, ensuring a holistic approach to dental care.
Recent achievements include the launch of the DEXIS digital ecosystem, an AI-powered platform designed to streamline implant dentistry workflows. This interconnected system combines cutting-edge CBCT, intraoral scanning, diagnostics, and treatment planning, empowering clinicians to manage implant cases efficiently.
Envista continues to innovate with products like the ORTHOPANTOMOGRAPH™ OP 3D™ LX, which enhances 3D diagnostic capabilities, and the IS ScanFlow software, which integrates AI-driven tools to maximize productivity in dental practices.
Financially, Envista reported sales of $623.6 million for the first quarter of 2024, with core sales growth and ongoing investments aimed at accelerating growth and profitability. The company has a proven track record of resilience and strategic differentiation, particularly through the challenges posed by the global pandemic and other economic factors.
Envista's philanthropic arm, the Envista Smile Project, exemplifies its commitment to social responsibility. The project has donated millions to improve access to oral health for underserved communities, partnering with institutions like the University of Southern California to enhance dental care for vulnerable populations.
Envista's significant market positions in attractive dental segments, coupled with its continuous improvement culture and innovation-driven approach, make it a pivotal player in the dental industry. For more information, visit the official website at www.envistaco.com.
Envista Holdings (NYSE: NVST) reported Q4 2024 results with sales of $653 million and core sales growth of 2.0% compared to Q4 2023. The company achieved an Adjusted EBITDA margin of 13.9% and demonstrated improved performance in implants across Nobel Biocare, Implant Direct, and Alpha-Bio brands. Spark aligners showed continued market share gains and gross margin improvement.
Financial highlights include operating cash flow of $132 million and free cash flow of $124 million, representing increases of 30% and 24% respectively over Q4 2023. Q4 net income was $1 million ($0.01 per share), compared to a loss of $217 million in Q4 2023. For the full year 2024, the company reported a net loss of $1,119 million.
Looking ahead to 2025, Envista projects core sales growth of 1-3%, adjusted EBITDA margins of approximately 14%, and adjusted earnings per share between $0.95 and $1.05.
Envista Holdings (NYSE: NVST) has announced its upcoming Capital Markets Day, scheduled for Wednesday, March 5, 2025, from 9:00 a.m. to 12:00 p.m. EST. The event will feature a management presentation and a Q&A session.
In-person attendance will require advance registration through IR@envistaco.com. For those unable to attend physically, the event and presentation will be webcast and made available for replay on the Events and Presentations section of investors.envistaco.com.
DEXIS, a dental imaging technologies leader, reflects on its 2024 achievements and announces plans for 2025. Key 2024 launches included the DEXIS digital ecosystem for streamlined implant workflow, the Ti2 Intraoral Sensor with AI capabilities, DEXIS Connect Pro for proactive device monitoring, and the ORTHOPANTOMOGRAPH OP 3D EX X-ray platform.
The company plans several innovations for 2025, including their first in-house developed intraoral scanner, AI enhancements, 3D imaging portfolio expansion, and DTX Studio Clinic workflow updates. These developments will be showcased at the Chicago Dental Society Midwinter Meeting in February and the International Dental Show in Cologne in March. Currently, over 150,000 DEXIS dental imaging devices are in use worldwide.
Envista Holdings (NYSE: NVST) has announced its upcoming fourth quarter 2024 financial results release, scheduled for Wednesday, February 5, 2025. The company has rescheduled its conference call to 2:30 PM PT on the same date.
The one-hour earnings call will be accompanied by a slide presentation and webcast available on the 'Investors' section of Envista's website. Participants can join via phone by dialing 800-225-9448 (U.S.) or +1 203-518-9708 (international) using conference ID #7185081. The webcast replay will be accessible for one year, and related materials will be posted on the company's website prior to the call.
Envista Holdings (NYSE: NVST) has scheduled its fourth quarter 2024 earnings conference call for Wednesday, February 5, 2025, at 2:00 PM PT. The call will include a slide presentation and is expected to last approximately one hour.
Investors can access the webcast through the 'Investors' section of www.envistaco.com. A replay will be available for one year following the presentation. For direct dial-in access, participants can call 800-225-9448 (U.S.) or +1 203-518-9708 (international) using conference ID #7185081.
The earnings press release, webcast slides, and related materials will be posted on Envista's website before the conference call.
Envista Holdings (NYSE: NVST) has announced its upcoming participation in the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Wednesday, January 15, 2025, from 9:45 – 10:25 am PT at the Westin St. Francis Hotel in San Francisco. An audio-only recording of the presentation will be available on Envista's Investor Relations website for 30 days following the event.
DEXIS showcased its latest AI-powered solutions at the ADF conference in Paris, featuring new intraoral scanners and imaging products. The company presented its ORTHOPANTOMOGRAPH® OP 3D™ EX with customizable field of view and AI-powered software integration. The exhibition also highlighted the IS 3800W wireless scanner, offering ultra-fast impression capture and lightweight design. The company's expanded portfolio aims to enhance diagnostic workflows, increase productivity, and improve patient experience through innovative features like Oral Compare for treatment visualization and SmileFy integration for treatment simulations.
Envista Holdings (NYSE: NVST) has released its 2023 Sustainability Report, highlighting significant progress in ESG initiatives. The report showcases notable achievements including a 26% reduction in Scope 1 greenhouse gas emissions and a 3.5% reduction in total emissions intensity. The company maintained 99% gender and ethnic pay equity in the U.S. and donated nearly $1.3 million through the Envista Smile Project.
The report outlines five key focus areas: Delivering Quality and Access, Supporting People and Community, Safeguarding the Environment, Centering Ethics and Compliance, and Practicing Good Governance. Envista implemented several Kaizen projects to enhance sustainability and operational efficiency in waste generation and energy use.
Envista Holdings (NYSE: NVST) has announced its upcoming participation in a fireside chat at the Evercore HealthCONx Conference. The event will take place on Tuesday, December 3, 2024, from 12:30 – 1:15 pm ET at the Loews Coral Gables Hotel in Coral Gables, Florida. An audio-only recording of the session will be available on Envista's Investor Relations website for up to 365 days after the event.
Envista Holdings (NYSE: NVST) reported Q3 2024 financial results with sales of $601.0 million, showing a core sales decline of 5.3% compared to Q3 2023. Net income decreased to $8.2 million ($0.05 per diluted share) from $21.5 million ($0.12 per diluted share) in Q3 2023. Adjusted net income fell to $21.1 million ($0.12 per diluted share) from $75.5 million ($0.43 per diluted share). Adjusted EBITDA decreased to $54.9 million from $123.5 million year-over-year. The company maintains its full-year 2024 guidance of -1% to -4% core sales growth and adjusted EBITDA margins between 10-12%.
FAQ
What is the current stock price of Envista Holdings (NVST)?
What is the market cap of Envista Holdings (NVST)?
What does Envista Holdings Corporation do?
What are the main segments of Envista's business?
What recent achievements has Envista made?
How did Envista perform financially in the first quarter of 2024?
What is the Envista Smile Project?
Who is the new CEO of Envista Holdings Corporation?
How does Envista support dental professionals?
What is the DEXIS digital ecosystem?
What is the Envista Business System (EBS)?
Where can I find more information about Envista Holdings Corporation?
